【光大研究每日速递】20251125

Real Estate - In October, the core 30 cities saw a total of 133 residential land transactions, down 33.2% year-on-year, with an average floor price of 9,279 yuan per square meter, a decrease of 4.5% year-on-year [4] - From January to October, the total area of residential land transactions in 100 cities decreased by 9% year-on-year, while the average floor price increased by 15% year-on-year [4] - The total transaction value of residential land in the core six cities reached 541.2 billion yuan, accounting for 44.7% of the total in 100 cities, indicating a further deepening of market differentiation [4] Non-ferrous Metals - Cable manufacturers' operating rates have increased for three consecutive weeks, with tight supply conditions persisting; the Q4 peak season for the power grid is expected to continue [5] - Air conditioning production in October decreased by 28% year-on-year, but there is a continuous improvement in production on a month-on-month basis [5] - The supply-demand balance for copper is expected to remain tight, with copper prices likely to continue rising after short-term fluctuations [5] Electric Power and Environmental Protection - The hydrogen ammonia methanol sector is expected to attract more investment as a key direction for new energy consumption and green electricity applications [6] - The ongoing electricity shortage in the U.S. presents opportunities for rebound in underperforming sectors such as overseas energy storage and solid-state batteries [6] - The independent energy storage bidding in China for 2026 is expected to maintain a favorable level compared to 2025 [6] Public Utilities - The domestic thermal coal price remained stable week-on-week, while imported coal prices increased significantly [7] - In October, the total electricity consumption in China reached 8,572 billion kilowatt-hours, a year-on-year increase of 10.4% [7] Pharmaceuticals - The small nucleic acid drug sector is experiencing significant advancements, indicating the onset of a new wave of innovative drugs [8] - The industry is entering a golden development period driven by "technological breakthroughs + commercial realization," with many domestic pharmaceutical companies advancing to clinical research stages since 2025 [8] Company Analysis - Hangyang Co., Ltd. reported a revenue of 11.43 billion yuan for Q1-Q3 2025, a year-on-year increase of 10.4%, and a net profit of 760 million yuan, up 12.1% year-on-year [9] - The gross margin was 20.6%, an increase of 0.2 percentage points year-on-year, while the net margin was 7.4%, up 0.3 percentage points year-on-year [9]